Physician
Tyson Medical INC
Tyson Medical INC was paid $8.01M by Medicaid between Apr 2018 and Dec 2024, across 90 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 52% of everything it billed.
33Billing provider infoTYSON MEDICAL INC
EL CENTRO, CA 92243
EL CENTRO, CA 92243
33aNPI1376053843assigned 10/10/2017
33bProvider typeFamily Medicine Physician
28Total paid$8.01M
24GClaims190,824
24DCodes billed90
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#48 of 2,511
Median peer was paid$13K
This provider vs. median623×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,747 | $155K | |
| 2019 | 9,058 | $519K | |
| 2020 | 25,766 | $824K | |
| 2021 | 37,465 | $1.24M | |
| 2022 | 37,600 | $1.55M | |
| 2023 | 43,704 | $1.85M | |
| 2024incomplete | 35,484 | $1.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 52% | 40,760 | 36,650 | $4.19M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 18% | 14,748 | 14,694 | $1.41M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 11,228 | 10,242 | $1.03M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 5.9% | 5,558 | 5,536 | $473K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.1% | 2,621 | 2,333 | $246K |
| 99205 | Prolong outpt/office vis | 2.9% | 2,769 | 2,745 | $233K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 13,430 | 12,725 | $98K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 1.0% | 1,098 | 1,001 | $84K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,382 | 9,533 | $58K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,690 | 10,119 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,355 | 4,765 | $20K |
| 94760 | <1% | 12,165 | 10,610 | $17K |
78 more codes
| 86328 | <1% | 3,374 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,529 | $12K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,984 | $10K |
| 99072 | <1% | 11,145 | $9K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,064 | $7K |
| 81001 | <1% | 3,581 | $7K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 958 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,021 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,166 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,744 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 448 | $4K |
| 99195 | <1% | 625 | $4K | |
| 97597 | <1% | 613 | $3K | |
| 93000 | <1% | 740 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 267 | $3K |
| 81025 | <1% | 1,678 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 996 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,722 | $2K |
| 73130 | <1% | 671 | $2K | |
| 73630 | <1% | 582 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 690 | $1K |
| 79403 | <1% | 57 | $1K | |
| 73610 | <1% | 397 | $1K | |
| 90715 | <1% | 148 | $910.71 | |
| 99000 | <1% | 414 | $689.41 | |
| 86318 | <1% | 528 | $555.20 | |
| 81003 | <1% | 1,097 | $538.12 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 732 | $483.75 |
| 73110 | <1% | 117 | $455.21 | |
| 82962 | <1% | 500 | $451.33 | |
| 72110 | <1% | 26 | $408.38 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 687 | $406.59 |
| 87807 | <1% | 606 | $400.76 | |
| 80053 | Comprehensive metabolic panel | <1% | 504 | $391.83 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 24 | $359.04 |
| 74018 | <1% | 166 | $352.06 | |
| 73560 | <1% | 210 | $316.88 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 28 | $258.68 |
| 74022 | <1% | 53 | $217.10 | |
| 29540 | <1% | 41 | $158.14 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27 | $149.46 |
| 69210 | <1% | 27 | $139.82 | |
| 77086 | <1% | 42 | $136.30 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 171 | $134.85 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 338 | $134.57 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $125.20 |
| 87631 | <1% | 39 | $125.00 | |
| 87279 | <1% | 26 | $125.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 160 | $95.54 |
| 96373 | <1% | 54 | $59.55 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 101 | $49.29 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 96 | $12.12 |
| 82247 | <1% | 14 | $9.07 | |
| 86308 | <1% | 42 | $8.28 | |
| 84460 | <1% | 14 | $4.53 | |
| 84450 | <1% | 14 | $4.37 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $4.33 |
| 82565 | <1% | 14 | $4.27 | |
| 84075 | <1% | 14 | $4.09 | |
| 82310 | <1% | 14 | $4.06 | |
| 82040 | <1% | 14 | $3.98 | |
| 84550 | <1% | 14 | $3.97 | |
| 84295 | <1% | 27 | $3.47 | |
| 84132 | <1% | 27 | $3.41 | |
| 84520 | <1% | 14 | $3.12 | |
| 84155 | <1% | 14 | $2.93 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 215 | $2.15 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 29 | $1.78 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 17 | $0.28 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 35 | $0.06 |
| 36416 | 0% | 300 | $0.00 | |
| 87276 | 0% | 26 | $0.00 | |
| 86140 | 0% | 15 | $0.00 | |
| 72100 | 0% | 13 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 31 | $0.00 |
| 87275 | 0% | 38 | $0.00 | |
| 82947 | 0% | 13 | $0.00 | |
| 10060 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTYSON, BRIAN (CEO)